The goal of this randomised controlled, cross-over clinical trial is to compare High Flow Nasal Cannulas (HFNC) and Continuous Positive Airways Pressure (CPAP) in neonates over 34 weeks' amenorrhoea (SA) up to children weighing less than 20 kg with respiratory failure. The main question it aims to answer is the non-inferiority of high flows of high-flow nasal cannula compared with CPAP by analysis of diaphragmatic contraction (EAdi (Electrical activity of diaphragm)). Participants with respiratory failure and need of non invasive ventilation and nasogastric tube will receive 4 different increasing flows of HFNC and Positive End-Expiratory Pressure of 7 cmH2O with CPAP during 30 minutes for each flow rate and CPAP. The electrical activity of diaphragm and clinical data of the patient upon each flow and support will be collected. According to the cross-over procedure, the patients will change groups (increasing flows of HFNC or CPAP) in order to perform the remaining analysis.
With this research protocol, the investigators aim to demonstrate the non-inferiority of high flows of HFNC compared with CPAP on work of breathing (based on the intensity of contraction of diaphragmatic fibres and clinical aspects) in paediatric and neonatal patients. The investigators will also study the clinical tolerance and safety of these practices. Objectives : Main objective: To demonstrate the non-inferiority of high-flow nasal cannula flow rates compared with CPAP by analysis of diaphragmatic contraction (EAdi (Electrical activity of diaphragm)) in neonates over 34 weeks' amenorrhoea (SA) up to children weighing less than 20 kg in respiratory failure. Secondary objectives: * To compare different flows of HFNC (2 L/kg/min, 3 L/kg/min, 4 L/kg/min, 5 L/kg/min) with each other by analysing diaphragmatic contraction. * Compare the clinical effectiveness of different flow rates of HFNC with CPAP in young children in respiratory distress. * To compare the tolerability of different flow rates of HFNC with CPAP in the population of young children suffering from respiratory distress. * To compare the incidence of minor (digestive discomfort, digestive bloating, non-damaging skin lesions) and major (thoracic barotrauma, damaging skin lesions) side effects of different flow rates of HFNC with CPAP in young children in respiratory distress. * To describe the choice of support and settings (flow rates or PEEP levels) made by the practitioners in charge of the child after the study period. * To describe the epidemiological data from the paediatric intensive care and monitoring units and the neonatal intensive care unit. Type of study: Randomised controlled, cross-over, single-centre, non-inferiority trial of a medical device. Number of centres: 1 Study design: Upon admission to the department, if the eligibility criteria are met and the parents agree to the research , a wash-out period will be performed under low-flow oxygen therapy at 1 L/min to achieve SpO2 ≥ 94% for 15 minutes. The included patients will then be randomized into two separate groups: a CPAP group with PEEP at 7 cmH2O for 30 minutes and an HFNC group with increasing flow rates for up to 2 hours. The patients included will be their own controls and at the end of the first analysis, according to the cross-over procedure, the patients will change groups in order to perform the remaining analysis. A recourse procedure has been foreseen in case of failure of ventilatory support. Medical devices : Concerning HFNC ventilation: The nasal cannulas used are Optiflow® cannulas (Fisher and Paykel Laboratory) which will be adapted to the size of each patient's nostrils. The following sizes are available: * NICU patient: Optiflow Junior 2®. * PICU patient: Optiflow Junior 2®, Optiflow +®. Concerning CPAP ventilation: * For the neonatal population: * Medin Sindi® CPAP masks, caps and ties * Medin Miniflow® CPAP generators * For the paediatric population : * Medin Sindi® CPAP masks, caps and ties * Fisher and Paykel Healthcare CPAP masks, cannulas and caps * Miniflow® CPAP generators from Medin * Fisher and Paykel Healthcare CPAP generators Expected benefits : If it is shown that a reduction in the work of breathing is observed (EAdi and usual clinical signs) when HFNC flow rates are gradually increased, and that this increase to flow rates of 3 to 5 L/kg/min is well tolerated and does not increase the risk of barotrauma, HFNC ventilation at flow rates greater than 2 L/kg/min could be more widely proposed and accepted in the various units using it, as it is unanimously accepted in terms of tolerance and comfort for the patient compared with CPAP. Recruitment procedures The patients eligible for this study will be those admitted to the neonatal and paediatric intensive care unit of the Clermont-Ferrand University Hospital by a doctor on the unit and who meet the various inclusion criteria for the study. An information note has been drawn up and will be presented and explained to the child's legal representative(s) by an investigating doctor during their usual care, as well as to the child if his or her level of understanding is adequate, within 2 hours of admission to the department. The parents and the child will have a maximum of 1 hour to reflect (and a maximum of 3 hours from admission to the ward) between the time they are given the information and the time they sign the consent form. Legal representative(s) will then be asked to sign the written consent. The child's inclusion in the DiaworkHFNC protocol will be recorded in the child's computerised medical record (ICCA software).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Enrollment
80
CPAP and increasing flows of HFNC will be compared during a 30-minutes period each
CHU Clermont-Ferrand
Clermont-Ferrand, France
RECRUITINGVariations of mean max electrical activity of the diaphragm (mean EAdi) between different HFNC flows and between each HFNC flow and CPAP
Maximal EAdi will be measured in µV
Time frame: Maximal electrical activity of diaphragm will be recorded every minutes (up to 3 hours)
Variation in mean minimum EAdi (EAdi min) between different HFNC flows and between each HFNC flow and CPAP
Minimum EAdi will be measured in µV
Time frame: Minimal electrical activity of diaphragm will be recorded every minutes (up to 3 hours)
Variations of heart rate between the different rates of HFNC and between each rate of HFNC and CPAP
Heart rate will be measured in beats per minute (bpm)
Time frame: every 5 minutes during 3 hours
Variations of respiratory rate between the different rates of HFNC and between each rate of HFNC and CPAP
Respiratory rate will be measured in breath per minute
Time frame: every 5 minutes during 3 hours
Variations of oxygen saturation between the different rates of HFNC and between each rate of HFNC and CPAP
Oxygen saturation will be measured in percentage
Time frame: every 5 minutes during 3 hours
Variations of transcutaneous partial pressure of carbon dioxide between the different rates of HFNC and between each rate of HFNC and CPAP
Transcutaneous partial pressure of carbon dioxide will be measured in mmHg
Time frame: every 5 minutes during 3 hours
Variations of respiratory distress score between the different rates of HFNC and between each rate of HFNC and CPAP
score of Silverman (0 to 10), or score modified Wood score (0 to 10) or score of PRAM (0 to 12) depending on the pathology
Time frame: Every 30 minutes during 3 hours
Incidence of minor side effects for each HFNC flow rate and for CPAP
bloating and/or gastrointestinal discomfort with no other associated cause, low-grade skin trauma
Time frame: Every 30 minutes during 3 hours
Incidence of major side effects for each flow of HFNC and for CPAP
Barotrauma to the chest, pneumothorax or pneumomediastinum Bradycardia defined as : if \< 1 year: Heart rate (HR) \< 100 bpm for 20 seconds or \< 60 bpm for 5 seconds if ≥ 1 year: HR \< 100 bpm for 20 seconds or \< 40 bpm for 5 seconds Number of desaturations (oxygen saturation rate (SpO2) \< 88% for 3s), apneas (breathing pause ≥ 10s) High-grade skin trauma
Time frame: Every 30 minutes during 3 hours
Intubation rate
Time frame: through patient follow-up period, up to 3 hours
Ventilatory weaning time
Weaning from all types of pressure support
Time frame: From date of randomization until the date of pressure weaning support, up to 30 days.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.